Negative signs and symptoms secondary to antipsychotics: A double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers

American Journal of Psychiatry

Volumn 163, Issue 3, 2006, Pages 488-493

  Artaloytia, Juan Francisco ^b   Arango, Celso ^a   Lahti, Adrienne ^b   Sanz, Javier ^b   Pascual, Ana ^b   Cubero, Pedro ^b   Prieto, David ^b   Palomo, Tomás ^b  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; PLACEBO; RISPERIDONE; NEUROLEPTIC AGENT;

ADULT; AKATHISIA; APATHY; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONCENTRATION LOSS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HUMAN; LETHARGY; LOW DRUG DOSE; MALE; MOOD DISORDER; MOTOR DYSFUNCTION; NEGATIVE SYNDROME; PARKINSONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOMS; SCORING SYSTEM; SELF CONCEPT; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SUBJECTIVE DEFICIT SYNDROME SCALE; SYMPTOM; VOLUNTEER; ADOLESCENT; BEHAVIOR; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; EXTRAPYRAMIDAL SYNDROME; HEALTH STATUS; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; QUESTIONNAIRE; SCHIZOPHRENIA; SLEEP STAGE; STATISTICS;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BEHAVIORAL SYMPTOMS; BRIEF PSYCHIATRIC RATING SCALE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALOPERIDOL; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SLEEP STAGES;

EID: 33645925691     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.163.3.488     Document Type: Article

References (31)

1. Campan L, Lazorthes G: [The origin and success of neuroleptics.] Ann Anesthesiol Fr 1976; 17:1021-1024 (French)
2. Rifkin A, Quitkin F, Klein DF: Akinesia: a poorly recognized drug-induced extra pyramidal behavioral disorder. Arch Gen Psychiatry 1975; 32:672-674
3. Goldberg E: Akinesia, tardive dysmentia, and frontal lobe disorder in schizophrenia. Schizophr Bull 1985; 11:255-263
4. Lewander T: Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatr Scand 1994; 89(suppl 380):8-13
5. Awad AG: Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993; 19:609-618
6. Carpenter WT Jr, Heinrichs DW, Wagman AM: Deficit and non-deficit forms of schizophrenia: the concept. Am J Psychiatry 1988; 145:578-583
7. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT: The Schedule for the Deficit Syndrome: an instrument for research in schizophrenia. Psychiatry Res 1989; 30:119-124
8. Tollefson GD, Sanger TM: Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997; 154:466-474
9. Möller HJ: The negative component in schizophrenia. Acta Psychiatr Scand 1995; 91(suppl 388):11-14
10. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V (Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine): Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003; 290:2693-2702
11. Tandon R, Goldman R, DeQuadro JR, Goldman M, Perez M, Jibson M: Positive and negative symptoms covary during clozapine treatment in schizophrenia. J Psychiatr Res 1993; 27:341-347
12. Miller D, Arndt S, Andreasen NC: Negative symptoms in antipsychotic-naive schizophrenics and the effect of haloperidol (abstract). Biol Psychiatry 1994; 35:746
13. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM: Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151:1744-1752
14. Peralta V, Cuesta MJ, Martinez-Larrea A, Serrano JF: Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naive patients before and after treatment. Am J Psychiatry 2000; 157:1461-1466
15. Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr: A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 2001; 58:165-171
16. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151:20-26
17. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr: Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 1998; 155:751-760
18. Supplementary Drugs and Other Substances. London, Pharmaceutical Press (Royal Pharmaceutical Society of Great Britain), 2002, p 1628
19. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry 1997; 154(April suppl)
20. Schotte A, Janssen PF, Megens AA, Leysen JE: Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res 1993; 631:191-202
21. Kudo S, Takashi I: Pharmacokinetics of haloperidol. Clin Pharmacokinet 1999; 37:435-456
22. He H, Richardson JS: A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int Clin Psychopharmacol 1995; 10:19-30
23. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
24. Barnes TRE: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676
25. Kuenstler U, Juhnhold U, Knapp WH, Gertz HJ: Positive correlation between reduction of handwriting area and D2 dopamine receptor occupancy during treatment with neuroleptic drugs. Psychiatry Res Neuroimaging 1999; 90:31-39
26. Ventura J, Lukoff D, Nuechterlein KH: Appendix 1: Brief Psychiatric Rating Scale Expanded Version (4.0) scales, anchor points, and administration manual. Int J Meth Psychiatr Res 1993; 3:227-243
27. Andreasen NC: Modified Scale for the Assessment of Negative Symptoms (SANS). Iowa City, University of Iowa, 1984
28. Jaeger J, Bitter I, Czobor P, Volavka J: The measurement of subjective experience in schizophrenia: the Subjective Deficit Syndrome Scale. Compr Psychiatry 1990; 31:216-226
29. Luria RE: The validity and reliability of the visual analogue mood scale. J Psychiatr Res 1975; 12:51-57
30. Koehler K, Sauer H: Huber's basic symptoms: another approach to negative psychopathology in schizophrenia. Compr Psychiatry 1984; 25:174-182
31. Remington G, Kapur S, Zipursky R: APA practice guideline for schizophrenia: risperidone equivalents (letter). Am J Psychiatry 1998; 155:1301-1302